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The X-linked McLeod neuroacanthocytosis syndrome (MLS) has originally been denoted as ‘benign’ McLeod
myopathy.We assessed the clinical findings and the muscle pathology in the eponymous index patient, Hugh
McLeod, and in nine additional MLS patients.Only one patient hadmanifested with neuromuscular symptoms.
During a mean follow-up of 15 years, however, eight patients including the initial index patient showed elevated
skeletal muscle creatine kinase levels ranging from 300 to 3000U/L, and had developed muscle weakness and
atrophy. Two patients had disabling leg weakness. Muscle histology was abnormal in all 10 patients. Clear but
unspecific myopathic changes were found in only four patients. All patients, however, had neurogenic changes
of variable degree. Post-mortemmotor and sensory nerve examinations support the view that muscle atrophy
and weakness are predominantly due to an axonal motor neuropathy rather than to a primary myopathy.
Multisystem manifestations developed in eight patients at a mean age of 39 years. Three patients manifested
with psychiatric features comprising schizophrenia-like psychosis and personality disorder, two presented with
generalized seizures and onewith chorea.During follow-up, seven patients developed chorea, six had psychiatric
disorders, five had cognitive decline and three had generalized seizures. Five patients died because of MLS-
related complications including sudden cardiac death, chronic heart failure and pneumonia between 55 and 69
years. In conclusion, our findings confirm that MLS is not a benign condition but rather a progressive multi-
system disorder sharing many features with Huntington’s disease.
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Introduction
The X-linked McLeod neuroacanthocytosis syndrome (MLS)
is a multisystem disorder with central nervous system (CNS)
features resembling Huntington’s disease (Walker et al.,
2007b). MLS is defined by absent expression of the Kx red
blood cell (RBC) antigen, diminished expression of Kell
glycoprotein RBC antigens, and RBC acanthocytosis (Allen
et al., 1961; Lee et al., 2000). About 150 individuals carrying
this so-called McLeod blood group phenotype are known to
date, and virtually all of them have elevated serum creatine
kinase (CK) levels (Danek et al., 2001; Danek et al., 2005).
Since weakness in these patients may be subclinical or mild,
the term ‘benign X-linked myopathy with acanthocytes’ was
used in this journal when the syndrome first attracted the
attention of neurologists (Swash et al., 1983). Many patients,
however, develop clinically relevant muscle weakness or
atrophy during the disease course, which in some patients is
disabling and may predispose to rhabdomyolysis (Danek et al.,
2001; Kawakami et al., 1999; Jung et al., 2001a; Jung and
Brandner, 2002).
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Most carriers of the McLeod blood group phenotype
develop additional CNS abnormalities at a mean onset
age of 40 years (Danek et al., 2001; Jung et al., 2001a;
Danek et al., 2005; Walker et al., 2007b). CNS manifesta-
tions resemble Huntington’s disease and comprise
hyperkinetic movement disorders, psychiatric abnormalities,
cognitive alterations, as well as epileptic seizures (Danek
et al., 2001; Jung et al., 2001a; Danek et al., 2005; Walker
et al., 2007b). These CNS manifestations may appear several
decades after the immunohaematological diagnosis,
progress relentlessly, and may lead to a considerable
impairment of everyday activities (Danek et al., 2001;
Jung et al., 2001a; Walker et al., 2007b).
We describe the clinical features and the muscle biopsy
findings of 10 McLeod patients from 8 different families,
and delineate a clearly not benign neuromuscular and
neurodegenerative disorder.
Methods
Patients
The patients originated from eight families from the United States,
Germany, Switzerland and Chile (with German ancestors). Their
clinical findings have previously been documented to a variable
extent (Table 1). The series included the eponymous case of Hugh
McLeod, whose clinical course, so far unreported, will be detailed
below. Neurological and cognitive examination was performed in
all patients and structured cognitive data were available in five
patients (Table 1). Immunohaematological analysis of Kx and Kell
expression, acanthocyte count and serum CK levels were available
from all patients whereas sequence analysis of the XK gene was
not performed in one (Table 2). Results of other technical
examinations available were listed in the table (Table 2).
Muscle pathology
Tissue samples originated from quadriceps (cases 1, 2, 4, 5, 7–10)
gastrocnemius (case 3) and deltoid muscles (case 6; Table 3), and
were obtained by biopsy (cases 1–6, 9 and 10) or autopsy (cases 7
and 8). Findings were previously reported from cases 1 and 3
(Danek et al., 2001), case 6 (Jung et al., 2001b), case 9 (Jung et al.,
2003) and case 10 (Oechsner et al., 1996). Frozen muscle samples
stored at 80C were available from all but the index patient
(case 8), in whom formalin-fixed autopsy tissue and slides from
frozen tissue of a muscle biopsy were available (Table 3).
All muscle specimens were processed (or reprocessed) and
analysed in a standardized way. Cryostat sections were cut at a
thickness of 10 mm and stained according to standard protocols
with haematoxylin-eosin (H&E), modified Go¨mo¨ri trichrome,
periodic acid-Schiff (PAS), Oil red O and Elastica-van Gieson
(EvG). Fibre typing was performed using immunohistochemical
stainings for myosin heavy chain-slow and myosin heavy chain-
fast isotypes (clone WB-MHCs, diluted 1:50 and clone WB-MHCf,
diluted 1:100, Novocastra, VisionBiosystems, Newcastle-upon-
Tyne, UK), corresponding to type 1 and type 2 fibres, respectively.
Additional immunohistochemical stains included dystrophin (Dys 1,
clone Dy4/6D3, 1:10, Novocastra Newcastle-upon-Tyne, UK),
spectrin (clone RBC/3D5, 1:100, Novocastra Newcastle-upon-
Tyne, UK), and CD45 (leukocyte common antigen, LCA, clones
2b11 + PD7/26, 1:10, DAKO, Switzerland). Enzyme histochemistry
was performed for cytochrome-c oxidase (COX), succinate
dehydrogenase (SDH), and NADH dehydrogenase (NADHD).
Formalin-fixed, paraffin-embedded tissue was available from four
patients (cases 6–9). Sections were cut at a nominal thickness of 4
mm and stained with H&E, EvG, PAS and myosin heavy chain fast
and slow isotypes.
We performed fibre size measurement using the analySISTM
morphometry software package (Olympus, Switzerland).
Representative muscle regions were selected, and for type 1 and
type 2 fibres were measured on the basis of their ‘lesser diameter’,
defined as the maximum distance at a right angle to a fibre’s
longest diameter. Frequency of internalized nuclei was defined by
the number of internalized nuclei per 100 fibres in the selected
region. Variability, hypertrophy and atrophy coefficients were
calculated according to commonly used definitions (Brooke and
Engel, 1969). At least 150 fibres per sample were measured. Mean
fibre diameter, variability, atrophy and hypertrophy coefficients
were calculated for type 1 and type 2 fibres, respectively. Although
no formal cut-off values are available, variability coefficients
above 250, and atrophy and hypertrophy coefficients above
250–350 are commonly considered as clearly pathological
(Brooke and Engel, 1969).
Nerve pathology
For conventional nerve histology, paraffin-embedded nerve
samples obtained at autopsy were available from cases 7 (femoral
and sural nerves) and 8 (peroneal and sural nerves). Sections were
cut at a nominal thickness of 4 mm and stained with H&E and
EvG, and immunohistochemically reacted for neurofilament and
myelin basic protein.
Semithin sections and electron microscopy
Resin-embedded tissue was available from case 6 (deltoid muscle),
case 7 (quadriceps muscle, femoral and sural nerves) and case 9
(quadriceps muscle). Formalin-fixed tissue from case 8 (quad-
riceps muscle, peroneal and sural nerves) was post-fixed with
glutaraldehyde and subsequently embedded in epon resin.
Semithin and ultrathin sections were prepared according to
standard protocols.
Results
Case report of Hugh McLeod
The initial index patient (case 8) had been identified during
screening for allogenic antibodies while he was a Harvard
dental student at the age of 25 years. His RBC’s had shown
an unexplained weak reactivity to Kell antisera and thus
defined the Kell blood group phenotype that came to be
known by his name (Allen et al., 1961; Danek, 2004).
General areflexia was noted at about that time.
Subsequently, Dr McLeod episodically donated blood for
patients with chronic granulomatous disease and the
McLeod phenotype (Giblett et al., 1971), an association
later shown to be due to a contiguous gene syndrome
(Francke et al., 1985). At age 35 years, acanthocytosis was
first detected (Wimer et al., 1977) and soon after, high
serum CK levels were noted (Marsh et al., 1981).
At age 51 years, physical examination revealed moder-
ately increased weight (body mass index-BMI-of 29.7),
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Table 1 Clinical findings
Patienta Earlier report
of case
Age at
onset
(years)
Initial
Presentation
Age at last
examination
Muscle
weakness
Muscle
atrophy
Clinical
signs of
cardiopathy
PNS Chorea; age
of onset
(years)
Other
movement
disorders
Last
UHDRS
Psychiatric
Symptoms;
age of
onset (years)
Cognitive
alterations;
age of onset
(years)
1 Case 16 of
Danek et al.
(2001a)
43 Seizure 62b UL no
LL M4
LL slight No UL and LL
areflexia
PNP
UL, LL; 51 FD, IV
Dysarthria
n.d. Paranoid
delusions; 43
Moderate; 43
2 Case 2 of
Walker et al.
(2007c)
n.a. None; McLeod
blood group
phenotype
57 No No No No No No n.d. No No
3 Case 1 of Danek
et al. (2001a)
26 Exercise
intolerance
34 UL no
LL M4
No No LL areflexia No No 10 No No
4 Brother of
case 5
Case 1 of
Miranda et al.
(2007)
23 Schizophrenia 57b UL M4
LL M1-2
UL moderate
LL severe
No UL and LL
areflexia
PNP
Trunk, UL; 41 FD IV
Dysarthria
n.d. Schizophrenia; 28 Moderate; 46
MMS 23
5 Brother of
case 4
Case 2 of
Miranda et al.
(2007)
48 Chorea 56 UL M4
LL M4
UL slight
LL slight
No UL and LL
areflexia
PNP
Trunk, UL; 40 FD, IV
Dysarthria
n.d. Obsessive-compulsive
disorder; 50
No
6 Cousin of
case 7
Case IV-13 of
Jung et al.
(2001)
25 Personality
disorder
55b UL M4-5
LL M3-4
UL slight LL
moderate
No UL and LL
areflexia
Trunk, UL, LL;
30
FD, Dystonia 61 Personality
disorder; 25
Moderate; 45
ERFC 39.5/50
7 Cousin of
case 6
Case IV-5 of
Jung et al.
(2001)
39 Schizophrenia 55b UL no
LL M4-5
UL slight LL
moderate
No UL and LL
areflexia
Trunk, UL. LL;
50
Dysarthria 38 Schizophrenia; 39 Mild; 48
MMS 25/30
8 (Index) Case 21 of
Danek et al.
(2001a)
n.a. None; McLeod
blood group
phenotype
69b UL no
LL M3-4
UL no
LL slight
Dyspnoea UL and LL
areflexia
decreased
vibration
sense LL
UL, 64 No n.d. No No
9 Case II-2 of
Jung et al.
(2003)
n.a. None; McLeod
blood group
phenotype
52 No No No No No No 0 No No
ERFC 50/50
10 Case 4 of
Oechsner
et al. (1996)
58 Generalized
Seizure
61 ULM4
LL M1-3
UL moderate
LL severe
No UL and LL
areflexia
PNP
Trunk, UL, LL;
48
FD, IV
Dystonia
TLB
n.d. Schizophrenia,
compulsion,
personality
disorder; 48
Moderate; 58
MMS 20/30
ERFC=e¤ valuation rapide des fonctions cognitives; a population-based validated method for short and comprehensive cognitive testing (Gil et al., 1986); FD= facial dyskinesia;
IV= involuntary vocalizations; LL= lower limbs; MMS=mini mental state examination; n.a.=not applicable; n.d.=not determined; PNP=polyneuropathy; PNS=peripheral
nervous system; TLB=tongue and lip biting; UHDRS=Unified Huntington’s Disease Rating Scale; UL=upper limbs.
aPatients are listed according to the position of the mutation in the XK gene. bAge at death.
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Table 2 Technical findings
Patient Kell blood group
phenotype
XK mutation RBC
Acantho-
cytes (%)
CK min-max
(U/l)
ECG Echo EEG EMG ENG Cerebral MRI/CTMuscle
MRI
Cerebral
SPECT/PET
1 K2 (+), K4+, K5 0,
K7 +, K9 0, K11 0,
K17 0
50 000bp major
deletion
3 100^1200 AF LVSD
EF 38%
n.d. Normal Sensory-motor
axonal
Caudate atrophy n.d. IBZM-SPECT: decreased
striatal D2- binding;
PET: decreased stria-
tal FDG-uptake
2 Kx 0, K1 0, K2 +, K3 0,
K4 +, K5 +, K6 0,
K7 +, K17 0 K21 0
IVS2+5G4A 51 20 Normal Normal n.d. n.d. n.d. Mild caudate
atrophy
n.d. n.d.
3 Kx 0, K20 0 768^769delTT 5 400^1190 Normal n.d. Normal Normal Sensory axonal Normal n.d. IBZM-SPECT: normal;
PET: decreased stria-
tal FDG-uptake left
4 Kx 0, K1 0, K2 +, K3 0,
K4 0
938^
942delCTCTA
3 (26a) 300 Normal n.d. Normal Myopathic
No SA
Normal Caudate
atrophy
n.d. ECD-SPECT: caudate
hypoperfusion
5 Kx 0, K1 0, K2 +, K3 0,
K4 0
938^
942delCTCTA
2 (35a) 300 Normal n.d. Normal Myopathic
No SA
Normal Caudate
atrophy
n.d. ECD-SPECT: caudate
hypoperfusion
6 Kx 0, K1 0, K2 (+), K3 0,
K4 (+), K5 (+), K7 (+)
977C4T 20 3000 Normal Normal n.d. n.d. n.d. Caudate and
putamen
atrophy
n.d. PET: decreased striatal
FDG-uptake
7 Kx 0, K1 0, K2 (+), K3 0,
K4 (+), K5 (+), K7 (+)
977C4T 18 1500^160 820 Normal Excentric LVH
EF 43%
n.d. n.d. n.d. Mild caudate
atrophy
n.d. PET: decreased striatal
FDG-uptake
8 (Index)Kx 0, K1 0, K2 (+), K3 0,
K4 (+), K5 (+), K6 0,
K7 (+), K11 +, K12 +,
K13 (+), K14 (+),
K 18 (+), K17 0
1020-1033del 8^85 1000 AF
LAFB
EF reduced;
enlargement
LA and RV
n.d. Neurogenic
SA
Sensory-motor
axonal
Mild caudate and
general cere-
bral atrophy
Fatty
degeneration
n.d.
9 Kx 0, K1 0, K2 +, K3 0,
K4 +, K7 +
1061G4A 0 298 Normal Normal n.d. n.d. n.d. Normal n.d. FDG-PET: normal
10 Kx 0, K20 0 n.d. 5 120^1600 Normal n.d. Left temporal
theta focus,
no epileptic
activity
Myopathic
Neurogenic
SA
Sensory-motor
axonal
Caudate
atrophy
n.d. n.d.
AF=Atrial fibrillation; CT=computed tomography; Echo=echocardiography; ECG=Electrocardiogram; EEG=electoencephalography; EF=ejection fraction;
EMG=electromyography; ENG=electroneurography; LA= left atrium; LAFB= left anterior fascicular block; LVH= left ventricular hypertrophy; LVSD= left ventricular systolic dys-
function; MRI=magnetic resonance imaging; n.d.=not determined; RV=right ventricle; PET=positron emission tomography; SA=pathological spontaneous activity; SPECT=single
photon emission computed tomography.
a1:1 dilution with saline.
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normal blood pressure, and slightly irregular cardiac
rhythm with marked splitting yet otherwise normal
cardio-pulmonary findings. The spleen was palpated
11 cm below the costal margin. Neurological examination
demonstrated moderately reduced strength of hamstrings
and toe extensors (MRC grade 4), areflexia and decreased
vibration sense at the ankles yet otherwise normal
sensation. Electrophysiology was compatible with a sensory
and motor axonal neuropathy. Nerve conduction studies
demonstrated an absence of sural nerve action potentials as
well as absent or prolonged F-waves in the legs, with motor
velocities at the lower range of normal. Electromyography
disclosed high-amplitude interference patterns in distal arm
and leg muscles. In addition, rare fibrillations and fascicula-
tions were found. At age 54 years, electrocardiography (ECG)
showed left axis deviation, sinus bradycardia and left anterior
fascicular block. Echocardiography showed normal but
somewhat globular left ventricular size, mildly reduced
systolic function, and a mild enlargement of the left atrium
as well as the right heart chambers. At age 60 years, leg
weakness had slightly progressed, with particular difficulty
walking on toes, and there were a positive Trendelenburg sign
and atrophy of thigh and foot muscles. A movement disorder
was not observed and no cognitive alterations were reported.
In the following years, while still working as a dentist, he
developed progressive proximal weakness, with difficulty
walking upstairs and inability to take more than 10 steps in
succession. In addition, atrial fibrillation was noted and oral
anticoagulation was started. At age 64 years, a movement
disorder was noted for the first time, described as repetitive
right arm shoulder shrugs. His condition deteriorated
further, with increasing immobility because of weakness,
obesity (BMI 40) and shortness of breath. Hugh McLeod died
at the age of 69 years from heart failure.
Clinical and paraclinical findings
The clinical and paraclinical findings are summarized in
the tables (Tables 1 and 2). By definition, all patients had
absent Kx RBC antigen and weak Kell antigens. In three
individuals, including the initial index patient, this McLeod
blood group phenotype had been incidentally detected in
blood banks (cases 2, 8 and 9). In standard blood smears,
significant RBC acanthocytosis of more than 5% was found
in three patients (cases 6–8). Five additional patients also
showed acanthocytosis but less than 5% (cases 1, 3–5 and 10).
In two individuals, no acanthocytes were detected (cases 2
and 9). In two patients (cases 4 and 5), a standardized
method was applied to increase the sensitivity of acantho-
cyte determination by using a dilution with 1:1 isotonic
saline and phase contrast microscopy, thus considerably
increasing acanthocyte numbers (Storch et al., 2005). Serum
CK levels were elevated in eight patients, ranging from 300
to 3000U/L. Case 7 experienced an episode of massive
rhabdomyolysis possibly related to neuroleptic medication,
with CK levels up to 160820U/l and consequent renal
failure (Jung and Brandner, 2002). Case 9 had serum CK
levels at the upper limit of the normal range (298U/L;
normal for the laboratory5300) and case 2 had entirely
normal levels.
These latter two individuals did not show CNS or
neuromuscular symptoms at the last follow-up examination
at the age of 57 years (case 2) and 52 years (case 9),
respectively. Age of onset of CNS or neuromuscular
symptoms in the remaining patients ranged between 23
and 58 years (mean 39 years). Only one patient presented
with a choreatic movement disorder (case 5). During
follow-up, however, seven patients developed chorea that
mainly affected trunk and arms (cases 1, 4–8 and 10).
Additional movement disorders included facial dyskinesia
(cases 1, 4–6 and 10), involuntary vocalizations (cases 1, 4,
5 and 10), dysarthria (1, 4, 5 and 7), dystonia (6 and 10)
and involuntary tongue and lip biting (case 10). Three
patients presented with psychiatric manifestations (schizo-
phrenia in cases 4 and 7; personality disorder in case 6),
and three further patients developed psychiatric disorders
during the disease course (paranoid delusion in case 1;
Table 3 Muscle histology
Patient Muscle Myopathic alterations Neurogenic alterations
Increased fibre
size variation
Necrosis Internalized
nuclei per
fibre population
Endomysial
fibrosis
Fibre group
atrophies
Angulated fibres Fibre-type
grouping
Fibre-type
predominance
(type)
1 Quadriceps   6    ++ 
2 Quadriceps   4    (+) 
3 Gastrocnemius (+)  3  (+) (+) ++ 
4 Quadriceps   5    ++ 2: ++
5 Quadriceps   2    + 1: +
6 Deltoid +  24  ++ + + 1: ++
7 Quadriceps +  5  + (+) + 
8 (Index) Quadriceps +  21 + + + + 
9 Quadriceps   1     2: ++
10 Quadriceps   16    ++ 
 indicates absent; (+) indicates subtle/rare; + indicates moderate/occasional; ++ indicates pronounced/frequent.
Mcleod myopathy revisited Brain (2007), 130, 3285^3296 3289
obsessive-compulsive disorder in case 5; schizophrenia,
compulsion and personality disorder in case 10). There was
no clinical evidence for tardive dyskinesia in any patient: In
one patient (case 5), the choreatic movement disorder was
present before the onset of the psychiatric disorders.
Neuroleptic treatment was only initiated after onset of the
movement disorder (case 4) or was not used at all (cases 1,
8 and 10). In a further case (case 7), typical chorea without
features of tardive dyskinesia appeared with a longer delay
of several months after the use of clozapine with gradual
progression.
Whereas no patient had cognitive impairment at the
initial examination, in five patients (cases 1, 4, 6, 7 and 10)
it subsequently developed to a variable degree, with a mean
onset age of 48 years. Generalized seizures were the
presentation of two patients (cases 1 and 10), and occurred
during follow-up in a third patient at the age of 56 years
(case 4).
EEG was abnormal in only one of five patients examined
(case 10). Cerebral imaging was normal in two patients
(cases 3 and 10) but caudate atrophy of variable degree
with consequent enlargement of the lateral ventricles was
found in the remaining eight cases studied. One patient
each had additional atrophy of putamen (case 6) or mild
generalized cerebral atrophy (case 8). IBZM–SPECT
demonstrated decreased striatal D2-binding in one patient
(case 1) and was normal in another patient (case 3). ECD–
SPECT and FDG–PET showed reduced striatal tracer
uptake in six patients (cases 1 and 3–7). One individual
had a normal FDG–PET (case 9) (Jung et al., 2003).
Only one patient had a neuromuscular presentation
(case 3), but neuromuscular features developed in alto-
gether eight cases during the disease course. Weakness and
atrophy affected mainly the legs and were distally
pronounced. Two patients had considerable walking
problems due to pronounced leg weakness (cases 4 and
10) and two additional patients (cases 6 and 8) had
moderate weakness and atrophy of their lower limbs. Four
patients had mild lower limb weakness and atrophy (cases
3, 5 and 7). Generalized areflexia was noted in eight
patients, and lower limb areflexia was found in an
additional patient (Table 1). Sensory findings were present
in 4 patients (cases 1, 4, 5 and 10).
EMG demonstrated myopathic alterations in three
patients (cases 4, 5 and 10), neurogenic alterations in 2
patients (case 8 and 10), and was normal in two patients
(cases 1 and 3). NCV studies demonstrated axonal changes
in 4 patients (cases 1, 3, 8 and 10). The two patients with
myopathic EMG alterations had normal NCV studies (cases
4 and 5). Lower leg MRI was reported with muscle atrophy
and fatty degeneration in the index patient (case 8).
The index patient had clinical signs and symptoms
suggesting chronic heart failure. ECG demonstrated atrial
fibrillation in two patients (cases 1 and 8) and was normal
in the remaining eight patients. Echocardiography was
normal in two of five patients examined (Table 2). Three
patients (cases 1, 7 and 8) had left ventricular systolic
dysfunction of variable degree, and one of them (case 7)
also had left ventricular hypertrophy. The index patient
(case 8) had asymmetric dilatation of the left atrium and
the right ventricle (Table 2).
Five patients died because of MLS-related complications
including sudden cardiac death (cases 1, 6 and 7), chronic
heart failure (case 8), and pneumonia (case 4) between 55
and 69 years (mean age at death 59.6 years; mean disease
duration 23.4 years).
Molecular genetic analysis
Sequence analysis of the XK gene was performed in all but
one patient (case 10; Table 2). A major deletion including
the entire XK gene was found in one patient (case 1), and
minor deletions in four other patients (cases 3–5, 8). One
patient had a splice-site mutation (case 2). Two brothers of
the Chilean family that originated from Germany had a
4 bp deletion leading to a frame shift and a premature stop
codon (cases 4 and 5). One patient had a 2 bp deletion
leading to a frame shift and a premature stop codon
(case 3). Two Swiss cousins had a nonsense mutation
leading to a premature stop codon (cases 6 and 7). All these
mutations predicted an absent or truncated XK protein
devoid of the Kell-binding site. One patient with absent
CNS and neuromuscular symptoms had a missense
mutation (case 9) (Jung et al., 2003). Except for the mild
phenotype in the patient with the missense mutation, there
was no clear correlation between clinical symptoms and the
position of the mutations in the gene.
Muscle histology
Sufficient preservation of muscle tissues was demonstrated
by normal spectrin immunohistochemistry in all muscles.
No structural abnormalities within muscle fibres were
observed. In particular, no vacuoles or inclusions were
present.
Enzyme histochemistry (COX, NADHD, SDH) showed
normal intensity as well as regular patterns of staining.
There was no evidence for accumulation of either glycogen
(PAS) or neutral lipids (Oil red O). Patterns and intensities
of dystrophin immunohistochemistry were normal in all
muscles analyzed.
Alterations suggesting a myopathic process were not
frequent and-if present-not pronounced (Fig. 1). The most
common finding was an increase in the number of
internalized nuclei. Three muscles (cases 6, 8 and 10)
demonstrated a clearly increased number of internalized
nuclei above 15%. One muscle (case 1) yielded borderline
abnormalities, with a fraction of 6% internalized nuclei.
The remaining muscles showed values of 5% or less
(Table 3). The three muscles with clearly increased numbers
(cases 6, 8 and 10) also showed increased fibre size
variation, and mild endomysial fibrosis was present in
one muscle (case 8). Only one muscle (case 6) had few
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Fig. 1 Muscle histology (A,B) The muscle autopsy of the index patient (case 8) demonstrates fibre-type grouping and numerous interna-
lized nuclei, while atrophic fibres were not frequently seen. (C^E) The muscle biopsy of case 6 shows the most pronounced pathology
of the present series with groups of atrophic and angulated fibres, some fibre-type grouping and frequent internalized nuclei. However,
the morphology of the individual muscle fibres was normal. E, F: The muscle biopsy of case 9 shows a predominance of type 2 fibres,
without additional abnormal findings. (G,H) The muscle biopsy of case 5 shows moderate pathology: While conventional morphology
was unremarkable and in particular atrophic fibres were absent, there was clear fibre-type grouping (Stainings: A, C^H&E; B, D,
F^immunohistochemistry for type 1 fibres-myosin heavy chain slow isoform-MHCs; E, G: trichrome; double immunohistochemistry
for MHCs and Dystrophin).
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CD45-positive leukocytes without evidence of polymyositis.
Signs of necrosis were not seen in any of the samples.
By contrast, all muscles displayed signs of an acute or
chronic neurogenic process with fibre type grouping of
variable degree that ranged from a few groups of both types
of fibres to an almost complete loss of the normal
checkerboard pattern in others (Table 3). In four muscles,
groups of atrophic fibres of variable extent as well as
occasional angulated fibres were seen (cases 3, 6–8). In two
muscles (cases 7 and 8), atrophic fibres belonged to both
fibre types. One sample each showed predominant atrophy
of type 1 (case 7) or type 2 fibres (case 3), respectively.
Although earlier reports suggested a predominance of type
1 fibres as a feature of neuromuscular pathology in the
McLeod syndrome, six muscles in our series (cases 1–3, 7, 8
and 10) showed an equal representation of both fibre types.
Two samples each showed predominance of type 1 fibres
(cases 5 and 7), and type 2 fibres (cases 4 and 9),
respectively (Table 3). The results of the morphometric
analysis are listed in Table 4, demonstrating normal mean
fibre diameters in all muscles, increased variability of fibres
diameters of type 1 and type 2 fibres in 6 muscles (cases 1,
3, 4, 6, 7 and 10), pathological atrophy coefficients in 2
muscles only for type 2 fibres (cases 6 and 7), and
pathological hypertrophy coefficients of type 1 and type 2
fibres in five muscles (cases 2–4, 7 and 8; Table 4).
The samples of the two patients without evidence of CNS
or neuromuscular involvement (cases 2 and 9) showed only
minimal alterations (fibre type grouping in case 2; fibre
type 2 predominance in case 9). Remarkably, the patient
with the deletion of the entire XK gene (case 1) showed
only moderate neurogenic alterations, and there were no
myopathic changes. The two patients with pronounced
walking difficulties (cases 4 and 10) had only moderate
neurogenic alterations in the muscle biopsy. However, this
might be misleading since the weakness was distally
pronounced, and biopsies were performed in the quadriceps
muscles in both patients.
Ultrastructural muscle pathology
None of the three samples available (cases 6, 7 and 9)
showed alterations of the sarcomeres or any of the other
muscle fibre compartments. In two muscles (cases 6 and 9),
however, occasional defects of the sarcolemma were seen.
Since the same observation could be made after rotation of
the section, this could not been simply attributed to
tangential cutting (Fig. 2). In the third sample (case 7),
obtained at autopsy, preservation of the sarcolemma was
insufficient to arrive at unequivocal conclusions.
Nerve pathology
Cross sections of sural and femoral nerves (case 7) or sural
and peroneal nerves (case 8) showed a pronounced loss of
myelinated fibres and both endoneural and perineural
fibrosis (Fig. 3). Digestion chambers that may indicate
recent axonal degeneration were not frequent. Onion bulbs,
a sign of primary demyelination, were not seen. Electron
microscopy (case 7, sural nerve) occasionally showed sheets
of Schwann cell processes devoid of axons, indicating
additional loss of unmyelinated axons, but ultrastructural
evidence of a primary demyelination was absent.
Discussion
Out of the 10 McLeod patients from eight families, only
two presented with neuromuscular symptoms. Initial serum
CK levels, by contrast, were clearly elevated in eight
patients, and all these successively developed weakness
and atrophy with distal and leg predominance and areflexia
was found at least of the lower limbs. Proximal muscles as
well as distal arm muscles were much less severely affected.
The remaining two patients showed a ‘McLeod phenotype
without the McLeod syndrome’ (Jung et al., 2003; Walker
et al., 2007a), and were free of neuromuscular symptoms
until their sixth decade. In our cohort of McLeod patients,
the proportion of patients who developed muscle weakness
and atrophy was 80% which exceeds the 59–68% reported
earlier (Danek et al., 2001). The proportion of 40% patients
with sensory signs or symptoms in the present study is
within the range of the previously describe rate of 27–59%
(Danek et al., 2001). Thus, subtle neuromuscular features
might have been overlooked in the past.
Predominant neurogenic alterations were found in the
muscle samples of all our patients. Myopathic changes, were
present in 4 out of 10 patients, but were less prominent
than neurogenic alterations. Although the myopathic
alterations might be secondary to the neurogenic process,
highly elevated CK levels in some patients and rhabdo-
myolysis in one patient point towards an additional
myopathy. Based on the pathological findings in our
cohort, however, the myopathy is far less prominent. The
significance of the ultrastructural alterations of the
sarcolemma remains unclear but suggests a defective
Table 4 Morphometry
Mean fibre
diameter (mm)
Variability
coefficient
Atrophy
coefficient
Hypertrophy
coefficient
Patient Type 1 Type 2 Type 1 Type 2 Type 1 Type 2 Type 1 Type 2
1 56.4 59.8 264 289 115 188 115 188
2 69.9 77.3 237 179 52 0 397 667
3 84.7 69.8 245 303 30 103 1403 641
4 86.8 66.9 260 216 38 24 1654 229
5 64.2 51.1 185 181 27 160 125 0
6 53.4 45.2 281 370 254 644 48 68
7 60.0 59.7 265 463 132 414 150 672
8 (Index) 69.1 62.6 232 192 32 34 372 86
9 54.2 61.2 161 192 0 22 0 65
10 50.8 53.4 263 220 297 137 31 0
Mean fibre diameter, variability, atrophy and hypertrophy
coefficients were calculated for type 1 and type 2 fibres,
respectively. Pathological values are marked in bold.
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plasma membrane. None of our patients had relevant
inflammatory changes as reported previously in a single
case (Barnett et al., 2000). Myopathic EMG alterations did
not predict myopathic findings upon muscle biopsy.
Presentation with neuromuscular symptoms and pro-
nounced atrophy, on the other hand, was not clearly
associated with more pronounced neurogenic alterations.
The two patients with pronounced walking difficulties had
only moderate neurogenic alterations in the muscles. This
might be explained by the fact that the weakness in these
patients was prominent in distal muscles but biopsy tissues
were taken from the less severely affected, proximal
muscles.
Previous reports of MLS muscle histology documented a
variety of unspecific changes such as type 1 fibre
predominance and type 2 fibre atrophy, but also clearly
myopathic changes such as increased fibre size variability
and increased numbers of centralized nuclei as well as fibre
type grouping that is usually considered as a reinnervation
phenomenon due to axonal neuropathy (Swash et al., 1983;
Witt et al., 1992; Malandrini et al., 1994; Jung et al., 2001b;
Dotti et al., 2004). The latter had been previously
interpreted as a myopathic finding in resemblance to
findings in female carriers of Duchenne muscular dystrophy
(Witt et al., 1992).
In line with previous observations, EMG demonstrated
myopathic as well as neurogenic changes in the majority of
patients (Danek et al., 2001). NCV studies were normal in
the two patients with purely myopathic EMG alterations,
but indicated sensory and motor axonopathy in all patients
with neurogenic EMG as well as in two patients with
normal EMG. In accordance with these findings, NCV
studies from the literature regularly suggested a mixed
axonal-demyelinating neuropathy (Malandrini et al., 1994;
Fig. 2 Muscle ultrastructure. Muscle ultrastructure was normal except for occasional sarcolemma defects, which remained unchanged
after goniometric analysis (i.e. rotation of the section by various angles; 40 0 +40). The arrows indicate borders between normal
sarcolemma and defects.
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Danek et al., 2001; Dotti et al., 2004). In contrast to the
unspecific sural nerve findings from single cases in the
literature, however, the samples available here give clear
structural evidence of a sensory-motor axonopathy in MLS.
Since spinal cord tissue was not available, we cannot decide
about an underlying anterior horn cell pathology. In
summary, electrophysiological as well as muscle and nerve
pathology findings in McLeod syndrome demonstrate
predominant neurogenic alterations underlying the clini-
cally observed areflexia, weakness and atrophy, yet lacking
disease-specific structural features. These findings strongly
support a motor neuropathy as the predominant cause of
weakness and atrophy in MLS, rather than a myopathy.
The majority of our patients developed a syndrome
similar to Huntington’s disease with chorea, psychiatric
manifestations and cognitive decline (Danek et al., 2001;
Jung et al., 2001a). Involuntary tongue and lip biting, a
hallmark of autosomal recessive chorea-acanthocytosis
(Walker et al., 2007b), was observed in only one patient.
Psychiatric disorders represented the initial manifestation in
three of our patients, and developed in more than half of
the patients during the disease course. Cognitive
abnormalities, not evident initially, developed during the
disease course in almost half the patients and were regularly
associated with psychiatric manifestations. Three patients
(30%) of our cohort had epilepsy, a proportion at the lower
range of the previously estimated prevalence of 27–73%
(Danek et al., 2001) The clinical characteristics of the two
pairs of patients harbouring the same mutation (cases 4 and
5 and 6 and 7, respectively) demonstrated a considerable
intrafamilial phenotypic variability. The follow-up of the
present cohort covered a mean of 15 years. It clearly
indicates a slow progression of the disease as documented
in the typical case of the eponymous index patient. Also
based on our previous observations, we propose that there
might be a complete clinical penetrance of MLS by the age
of 60 years (Danek et al., 2001; Walker et al., 2007c). Five
patients died because of MLS-related complications at a
mean age of 60 years and mean disease duration of over 20
years because of probable sudden cardiac death, chronic
heart failure and pneumonia indicating a clearly reduced
life-expectancy.
The majority of our patients had low acanthocyte counts.
Late appearance or even absence of acanthocytosis in
Fig. 3 Nerve pathology. The peroneal (A) and sural (B) nerves of case 8 show a marked loss of myelinated axons (MBP). In addition, EvG
staining demonstrates a pronounced endo- and perineural fibrosis (C). Semithin sections of the femoral nerve of case 7 show a moderate
loss of myelinated axons (D), which was more pronounced in the sural nerve (E).Ultrastructurally, no overt abnormalities of the remaining
myelinated axons were observed in the sural nerve (F). However, there were sheets of empty Schwann cell processes, indicating additional
loss of unmyelinated axons (F, arrow).
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neuroacanthocytosis syndromes has been reported pre-
viously (Sorrentino et al., 1999) Acanthocyte determination
after dilution of the blood with 1:1 heparinized saline,
however, raised the sensitivity considerably, also in two of
our patients available for this examination (Storch et al.,
2005). This underlines the importance to use such a
validated method in the evaluation of chorea patients.
Molecular genetic analysis of the XK gene revealed a
causative mutation in all cases available. As already noted in
the past, the vast majority of McLeod patients have loss of
function mutations in the XK gene (Ho et al., 1994; Walker
et al., 2007a). In such patients of our cohort, no clear
phenotype-genotype correlation was possible. In fact, the
patient with a large deletion of the entire XK gene lacked
pronounced neuromuscular symptoms and CNS symptoms
were not worse than in other patients. On the other hand,
missense or splice-site mutations in the XK gene can be
associated with only a mild phenotype and even absence of
symptoms for decades. One oligosymptomatic patient
carrying the R222G missense mutation that allows XK
protein expression in cell culture but leads to its absence on
RBC’s (Walker et al., 2007a), had clearly elevated CK levels
suggesting subclinical neuromuscular involvement. Another
individual with the E327K missense mutation and serum
CK levels at the upper limit of normal did not show any
cerebral pathology based on MRI and FDG–PET (Jung
et al., 2003). Few other McLeod patients with XK missense
mutations are known. One was associated with the
prototypic neuroacanthocytosis phenotype including
chorea, cognitive decline, and generalized seizures after
the age of 44 years (Danek et al., 2001), another showed
only moderate suppression of Kell antigens compared to
XK nonsense mutations (Russo et al., 2002).
Our data delineate MLS as a deleterious basal ganglia
disorder that resembles Huntington’s disease. Weakness
and atrophy are common and may seriously interfere
with mobility. Although myopathic alterations may occur,
the predominant neurogenic changes on muscle biopsy
as well as the neurophysiological findings suggest that
muscle weakness and atrophy are mostly due to motor
neuropathy. The euphemistic designation as ‘benign
X-linked myopathy with acanthocytes’ is misleading. MLS
clearly is not a pure myopathy nor is it benign and it
should be recognized as a potentially life-threatening
neurodegenerative condition.
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